Hydroxyurea induced perimalleolar ulcers

Kavitha Saravu, Praveen Velappan, Naik Lakshmi, Barkur Ananthakrishna Shastry, Joseph Thomas

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Hydroxyurea (HU) is an antineoplastic drug commonly used to treat chronic myeloproliferative disorders. Common dermatological side effects include hyperpigmentation, scaling, erythema, alopecia, desquamation of face and hands. Leg ulceration following HU therapy is less common and very few cases have been reported so far. Objective of this paper is to increase the awareness of hydroxyurea induced leg ulcers which will aid in the early diagnosis and appropriate treatment. The first case was a chronic myeloid leukemia (CML) patient on HU 1.5 g/day for 5 yr, who had bilateral painful perimalleolar ulcers for 6 months. The second case was a CML patient on HU 1.5 g/day for 3 yr who developed bilateral lateral malleolar ulcers. Third case was a polycythemia vera (PV) patient on HU 1 g/day for 5 yr who presented with painful medial malleolar ulcer of 2 months. The last case of our report was an elderly PV patient on HU 1.5 g/day for 2 yr and presented with lateral malleolar ulcer which persisted on reducing the dose of HU. In all the 4 cases the ulcers healed on stopping HU. Our report confirms the association of chronic hydroxyurea therapy and perimalleolar ulcers which respond promptly after discontinuation of the drug. The heightened awareness among the physicians will promote early diagnosis and prompt relief from the agonizing ulcers.

Original languageEnglish
Pages (from-to)177-179
Number of pages3
JournalJournal of Korean Medical Science
Volume21
Issue number1
Publication statusPublished - 01-02-2006

Fingerprint

Hydroxyurea
Ulcer
Polycythemia Vera
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Early Diagnosis
Myeloproliferative Disorders
Hyperpigmentation
Leg Ulcer
Alopecia
Erythema
Antineoplastic Agents
Leg
Therapeutics
Hand
Physicians

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Saravu, K., Velappan, P., Lakshmi, N., Shastry, B. A., & Thomas, J. (2006). Hydroxyurea induced perimalleolar ulcers. Journal of Korean Medical Science, 21(1), 177-179.
Saravu, Kavitha ; Velappan, Praveen ; Lakshmi, Naik ; Shastry, Barkur Ananthakrishna ; Thomas, Joseph. / Hydroxyurea induced perimalleolar ulcers. In: Journal of Korean Medical Science. 2006 ; Vol. 21, No. 1. pp. 177-179.
@article{e2482782946a4024a590279fd691467e,
title = "Hydroxyurea induced perimalleolar ulcers",
abstract = "Hydroxyurea (HU) is an antineoplastic drug commonly used to treat chronic myeloproliferative disorders. Common dermatological side effects include hyperpigmentation, scaling, erythema, alopecia, desquamation of face and hands. Leg ulceration following HU therapy is less common and very few cases have been reported so far. Objective of this paper is to increase the awareness of hydroxyurea induced leg ulcers which will aid in the early diagnosis and appropriate treatment. The first case was a chronic myeloid leukemia (CML) patient on HU 1.5 g/day for 5 yr, who had bilateral painful perimalleolar ulcers for 6 months. The second case was a CML patient on HU 1.5 g/day for 3 yr who developed bilateral lateral malleolar ulcers. Third case was a polycythemia vera (PV) patient on HU 1 g/day for 5 yr who presented with painful medial malleolar ulcer of 2 months. The last case of our report was an elderly PV patient on HU 1.5 g/day for 2 yr and presented with lateral malleolar ulcer which persisted on reducing the dose of HU. In all the 4 cases the ulcers healed on stopping HU. Our report confirms the association of chronic hydroxyurea therapy and perimalleolar ulcers which respond promptly after discontinuation of the drug. The heightened awareness among the physicians will promote early diagnosis and prompt relief from the agonizing ulcers.",
author = "Kavitha Saravu and Praveen Velappan and Naik Lakshmi and Shastry, {Barkur Ananthakrishna} and Joseph Thomas",
year = "2006",
month = "2",
day = "1",
language = "English",
volume = "21",
pages = "177--179",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "1",

}

Saravu, K, Velappan, P, Lakshmi, N, Shastry, BA & Thomas, J 2006, 'Hydroxyurea induced perimalleolar ulcers', Journal of Korean Medical Science, vol. 21, no. 1, pp. 177-179.

Hydroxyurea induced perimalleolar ulcers. / Saravu, Kavitha; Velappan, Praveen; Lakshmi, Naik; Shastry, Barkur Ananthakrishna; Thomas, Joseph.

In: Journal of Korean Medical Science, Vol. 21, No. 1, 01.02.2006, p. 177-179.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hydroxyurea induced perimalleolar ulcers

AU - Saravu, Kavitha

AU - Velappan, Praveen

AU - Lakshmi, Naik

AU - Shastry, Barkur Ananthakrishna

AU - Thomas, Joseph

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Hydroxyurea (HU) is an antineoplastic drug commonly used to treat chronic myeloproliferative disorders. Common dermatological side effects include hyperpigmentation, scaling, erythema, alopecia, desquamation of face and hands. Leg ulceration following HU therapy is less common and very few cases have been reported so far. Objective of this paper is to increase the awareness of hydroxyurea induced leg ulcers which will aid in the early diagnosis and appropriate treatment. The first case was a chronic myeloid leukemia (CML) patient on HU 1.5 g/day for 5 yr, who had bilateral painful perimalleolar ulcers for 6 months. The second case was a CML patient on HU 1.5 g/day for 3 yr who developed bilateral lateral malleolar ulcers. Third case was a polycythemia vera (PV) patient on HU 1 g/day for 5 yr who presented with painful medial malleolar ulcer of 2 months. The last case of our report was an elderly PV patient on HU 1.5 g/day for 2 yr and presented with lateral malleolar ulcer which persisted on reducing the dose of HU. In all the 4 cases the ulcers healed on stopping HU. Our report confirms the association of chronic hydroxyurea therapy and perimalleolar ulcers which respond promptly after discontinuation of the drug. The heightened awareness among the physicians will promote early diagnosis and prompt relief from the agonizing ulcers.

AB - Hydroxyurea (HU) is an antineoplastic drug commonly used to treat chronic myeloproliferative disorders. Common dermatological side effects include hyperpigmentation, scaling, erythema, alopecia, desquamation of face and hands. Leg ulceration following HU therapy is less common and very few cases have been reported so far. Objective of this paper is to increase the awareness of hydroxyurea induced leg ulcers which will aid in the early diagnosis and appropriate treatment. The first case was a chronic myeloid leukemia (CML) patient on HU 1.5 g/day for 5 yr, who had bilateral painful perimalleolar ulcers for 6 months. The second case was a CML patient on HU 1.5 g/day for 3 yr who developed bilateral lateral malleolar ulcers. Third case was a polycythemia vera (PV) patient on HU 1 g/day for 5 yr who presented with painful medial malleolar ulcer of 2 months. The last case of our report was an elderly PV patient on HU 1.5 g/day for 2 yr and presented with lateral malleolar ulcer which persisted on reducing the dose of HU. In all the 4 cases the ulcers healed on stopping HU. Our report confirms the association of chronic hydroxyurea therapy and perimalleolar ulcers which respond promptly after discontinuation of the drug. The heightened awareness among the physicians will promote early diagnosis and prompt relief from the agonizing ulcers.

UR - http://www.scopus.com/inward/record.url?scp=33144469521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33144469521&partnerID=8YFLogxK

M3 - Article

C2 - 16479088

AN - SCOPUS:33144469521

VL - 21

SP - 177

EP - 179

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 1

ER -

Saravu K, Velappan P, Lakshmi N, Shastry BA, Thomas J. Hydroxyurea induced perimalleolar ulcers. Journal of Korean Medical Science. 2006 Feb 1;21(1):177-179.